Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

eli lilly agreed to acquire kelonia, a cancer drug maker, in a deal worth up to $7 billion. kelonia is developing a technology to reprogram a patient's t-cells inside the body, known as in vivo car-t, so those cells can attack cancer.